NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $1.20 -0.01 (-0.83%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.15▼$1.2150-Day Range$0.96▼$1.2752-Week Range$0.93▼$6.44Volume9,968 shsAverage Volume26,254 shsMarket Capitalization$5.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends Get Bright Minds Biosciences alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Bright Minds Biosciences Stock (NASDAQ:DRUG)Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Read More DRUG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRUG Stock News HeadlinesJanuary 12, 2024 | msn.comPsyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And MoreDecember 6, 2023 | finance.yahoo.comBright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementJuly 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.November 12, 2023 | msn.comPsyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & MoreNovember 12, 2023 | finance.yahoo.comBright Minds Biosciences Inc. (DRUG.CN)October 25, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and DatesAugust 18, 2023 | seekingalpha.comDRUG Bright Minds Biosciences Inc.August 8, 2023 | msn.comBright Minds stock rallies ahead of conference call to discuss Phase 1 dataJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.August 8, 2023 | finance.yahoo.comBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101August 7, 2023 | msn.comBright Minds reports results from trial to treat refractory epilepsiesJuly 24, 2023 | benzinga.comCybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical TrialsJuly 20, 2023 | finance.yahoo.comBright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101July 12, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest ReportJuly 11, 2023 | msn.comBright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ ComplianceJuly 11, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Effective Date of Share ConsolidationJune 22, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finance.yahoo.comBright Minds Announces Proposed Share ConsolidationSee More Headlines Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRUG CUSIPN/A CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-80.64% Return on Assets-73.04% Debt Debt-to-Equity RatioN/A Current Ratio7.69 Quick Ratio7.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.92Miscellaneous Outstanding Shares4,430,000Free Float2,542,000Market Cap$5.32 million OptionableNot Optionable Beta1.54 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ian McDonald (Age 35)Co-Founder, CEO, President & Director Mr. Ryan E. S. K. Cheung B.Com. (Age 46)CA, CPA, Chief Financial Officer Comp: $87.44kDr. Jan Torleif Pedersen M.Sc. (Age 59)Ph.D., Chief Science Officer & Director Comp: $177.46kDr. Mark A. Smith M.D. (Age 69)Ph.D., Chief Medical Officer Comp: $238.66kDr. Emer Leahy M.B.A. (Age 57)Ph.D., Consultant Key CompetitorsJanoneNASDAQ:ALTSAptorum GroupNASDAQ:APMVBI VaccinesNASDAQ:VBIVPharmaCyte BiotechNASDAQ:PMCBUnicycive TherapeuticsNASDAQ:UNCYView All Competitors DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $1.43 at the start of the year. Since then, DRUG stock has decreased by 16.1% and is now trading at $1.20. View the best growth stocks for 2024 here. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its earnings results on Wednesday, May, 15th. The company reported ($0.10) earnings per share (EPS) for the quarter. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRUG) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
